scholarly journals Quantification of a cell-mediated immune response against varicella zoster virus by assessing responder CD4high memory cell proliferation in activated whole blood cultures

Vaccine ◽  
2019 ◽  
Vol 37 (36) ◽  
pp. 5225-5232
Author(s):  
Ahmad M. Haredy ◽  
Michihiro Takei ◽  
Shin-ichi Iwamoto ◽  
Masafumi Ohno ◽  
Mitsuyo Kosaka ◽  
...  
Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1457
Author(s):  
Dewald Schoeman ◽  
Burtram C. Fielding

Over the past 18 years, three highly pathogenic human (h) coronaviruses (CoVs) have caused severe outbreaks, the most recent causative agent, SARS-CoV-2, being the first to cause a pandemic. Although much progress has been made since the COVID-19 pandemic started, much about SARS-CoV-2 and its disease, COVID-19, is still poorly understood. The highly pathogenic hCoVs differ in some respects, but also share some similarities in clinical presentation, the risk factors associated with severe disease, and the characteristic immunopathology associated with the progression to severe disease. This review aims to highlight these overlapping aspects of the highly pathogenic hCoVs—SARS-CoV, MERS-CoV, and SARS-CoV-2—briefly discussing the importance of an appropriately regulated immune response; how the immune response to these highly pathogenic hCoVs might be dysregulated through interferon (IFN) inhibition, antibody-dependent enhancement (ADE), and long non-coding RNA (lncRNA); and how these could link to the ensuing cytokine storm. The treatment approaches to highly pathogenic hCoV infections are discussed and it is suggested that a greater focus be placed on T-cell vaccines that elicit a cell-mediated immune response, using rapamycin as a potential agent to improve vaccine responses in the elderly and obese, and the potential of stapled peptides as antiviral agents.


2020 ◽  
Vol 11 ◽  
Author(s):  
Chelsea Gerada ◽  
Tessa M. Campbell ◽  
Jarrod J. Kennedy ◽  
Brian P. McSharry ◽  
Megan Steain ◽  
...  

2018 ◽  
Vol 70 (2) ◽  
pp. 375-381 ◽  
Author(s):  
T.B. Roos ◽  
L.F.C. Avila ◽  
R.T. Sturbelle ◽  
F.L.L. Leite ◽  
G. Fischer ◽  
...  

ABSTRACT There have been significant efforts towards the development of more efficient vaccines for animal health. A strategy that may be used to improve vaccine efficacy is the use of probiotics to enhance the immune response of the host, leading to increased immunogenicity of antigen preparations. Bovine herpesvirus 5 (BoHV-5) is an example of an important animal pathogen for which vaccines have provided only limited protection. In this study, we examined the use of the probiotic Saccharomyces boulardii (Sb) as a potential adjuvant to improve vaccine efficiency. We found that the supplemented animals exhibited an enhanced systemic IgG antibody response toward a Th1 response in favor of IgG2a and increased mRNA expression levels of the cytokines IFN-y, IL-12, IL-17 and IL-10 in the spleen. These results suggest that Sb supplementation may provide a promising means for improving the efficiency of vaccines, particularly those that rely on a cell-mediated immune response.


2009 ◽  
Vol 1 ◽  
pp. OED.S2858 ◽  
Author(s):  
Robert E. Cone ◽  
Roshan Pais

The “immune privilege” that inhibits immune defense mechanisms that could lead to damage to sensitive ocular tissue is based on the expression of immunosuppressive factors on ocular tissue and in ocular fluids. In addition to this environmental protection, the injection of antigen into the anterior chamber or infection in the anterior chamber induces a systemic suppression of potentially damaging cell-mediated and humoral responses to the antigen. Here we discuss evidence that suggests that Anterior Chamber-Associated Immune Deviation (ACAID)a is initiated by an ocular response to moderate inflammation that leads to a systemic immunoregulatory response. Injection into the anterior chamber induces a rise in TNF-α and MCP-1 in aqueous humor and an infiltration of circulating F4/80+ monocytes that home to the iris. The induction of ACAID is dependent on this infiltration of circulating monocytes that eventually emigrate to the thymus and spleen where they induce regulatory T cells that inhibit the inductive or effector phases of a cell-mediated immune response. ACAID therefore protects the eye from the collateral damage of an immune response to infection by suppressing a future potentially damaging response to infection.


2001 ◽  
Vol 95 (6) ◽  
pp. 573-586 ◽  
Author(s):  
B. E. Thomas ◽  
K. Sridevi ◽  
N. Chopra ◽  
W. Haq ◽  
D. N. Rao

The Lancet ◽  
2001 ◽  
Vol 357 (9253) ◽  
pp. 360-361 ◽  
Author(s):  
John K Wiencke ◽  
Karl T Kelsey ◽  
Zheng-fa Zuo ◽  
Adriana Weinberg ◽  
Margaret R Wrensch

Sign in / Sign up

Export Citation Format

Share Document